99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation

G.J. Riely, S-H.I. Ou, Igor I. Rybkin, Alexander I. Spira, K. Papadopoulos, Joshua K. Sabari, Melissa L. Johnson, Rebecca S. Heist, Lyudmila Bazhenova, Minal Barve, J.M. Pacheco, Karen Velastegui, Cornelius Cilliers, Peter Olson, James G. Christensen, Thian Kheoh, Richard C. Chao, P.A. Jänne